PharmAthene Submits Response to DHHS Request for Proposals for SparVax(TM) - A Recombinant Protective Antigen Vaccine

Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. gove...

Full description

Saved in:
Bibliographic Details
Published inPR Newswire
Format Newsletter
LanguageEnglish
Published New York PR Newswire Association LLC 31.07.2008
Subjects
Agreements
Anthrax
Antigens
Biological & chemical terrorism
Biological & chemical weapons
Human subjects
Monoclonal antibodies
Pharmaceutical industry
Product development
Vaccines
ANNAPOLIS, Md
Online AccessGet full text

Cover

More Information
Summary:Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, unforeseen safety issues, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's public disclosure filings with the U.S. Securities and Exchange Commission (the "SEC").